CenterBook Partners’s Legend Biotech LEGN Stock Holding History

CenterBook Partners’s Portfolio LEGN Stock Details LEGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$13.1M	Buy	452,907 +248,304	+121%	+$6.7M	0.64%	27
2026 Q1	$3.7M	Sell	204,603 -8,421	-4%	-$161K	0.2%	133
2025 Q4	$4.63M	Buy	213,024 +67,493	+46%	+$1.93M	0.23%	117
2025 Q3	$4.75M	Buy	145,531 +39,863	+38%	+$1.47M	0.23%	116
2025 Q2	$3.75M	Buy	105,668 +30,789	+41%	+$998K	0.21%	131
2025 Q1	$2.54M	Sell	74,879 -48,912	-40%	-$1.75M	0.16%	163
2024 Q4	$4.03M	Buy	123,791 +48,126	+64%	+$1.99M	0.24%	123
2024 Q3	$3.69M	Sell	75,665 -78,409	-51%	-$4.18M	0.23%	122
2024 Q2	$6.82M	Buy	+154,074	New	+$7.11M	0.42%	67

Other funds holding LEGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return

CenterBook Partners's LEGN Position: Q2 2026 in Review

CenterBook Partners increased its Legend Biotech (LEGN) stake by 121% in Q2 2026, buying an estimated $6.7M and bringing the position to 452,907 shares worth $13.1M. The position accounts for 0.64% of the portfolio, ranked #27.

CenterBook Partners first reported a position in LEGN in Q2 2024 and has held it in 9 quarters since. 219 funds tracked by Wall St. Rank hold LEGN as of Q2 2026.

CenterBook Partners held 452,907 shares of Legend Biotech worth $13.1M as of Q2 2026.
CenterBook Partners bought 248,304 Legend Biotech shares in Q2 2026, an estimated $6.7M.
Legend Biotech made up 0.64% of CenterBook Partners's portfolio in Q2 2026, its #27 holding.
CenterBook Partners first reported a position in Legend Biotech in Q2 2024 and has held it in 9 quarters since.
219 funds tracked by Wall St. Rank held Legend Biotech as of Q2 2026.

Based on CenterBook Partners's 13F filing for Q2 2026, filed 11 Aug 2026.